Since RRM2B is significantly upregulated in CRC tissues and associated with poor prognosis [53], our data suggest that m6A/RRM2B-regulated GSH generation and mitochondria fusion are potential targets for CRC therapy. This evidence concerns the gene RRM2B and colorectal carcinoma.